Search results

The Criminal Justice Drug Abuse Treatment Studies 2 (CJ-DATS 2) was launched in 2008 with a focus on conducting implementation research in criminal justice settings. NIDA's ultimate goal for CJ-DATS 2 was to identify implementation strategies that maximize the likelihood of sustained delivery of evidence-based practices to improve offender drug abuse and HIV outcomes, and to decrease their risk of incarceration.

The Medication-Assisted Therapy (MAT) study focuses on implementing linkages to medication assisted treatment in correctional settings. During the study period community corrections staff engaged in training about addiction pharmacotherapies, while leadership in the corrections and treatment facilities engage in a joint strategic planning process to identify and resolve barriers to efficient flow of clients across the two systems.

This study includes 28 datasets and over 1,400 variables. The first five datasets for this study contain data on the baseline characteristics of the treatment and corrections sites that participated in the study as well as the characteristics of the staff working at those facilities. Opinions about Medication Assisted Treatment surveys were administered to personnel at the participating corrections and treatment sites (D6). Data on Inter-organization Relations between Probation and Parole staff with Treatment Providers were also collected (DS7-DS18).

Information was extracted from the charts of clients about their alcohol and opioid dependence as well as the referrals and treatment the clients received (DS19). Probation and parole officers and treatment providers were surveyed about monthly counts of referrals (DS20-DS21).

During the study 10 staff members from the community corrections agency and local treatment providers where MAT services were available were nominated to participate in a Pharmacotherapy Exchange Council (PEC). PEC members were involved with strategic planning for implementing changes to improve the usage of Medication-Assisted Therapy. PEC members were surveyed several times throughout the study.

PEC members completed surveys on how well the sites were adhering to the Organizational Linkages Intervention (OLI) process (DS22). Community corrections staff, PEC members and Connections Coordinators in the experimental group were surveyed about their perceptions of organizational benefits and costs associated with the MATICCE intervention (DS23). The PEC rated the Connections Coordinators (DS24)and the Connections Coordinators rate the PEC (DS25). PEC researchers completed surveys on how much of the OLI was completed (DS26) as well as what the sustainability of the changes made through the MATTICE project (DS27). The final dataset provides a key for who took the KPI (Key Performance Indicators) training and who was a PEC member (DS28).

The Criminal Justice Drug Abuse Treatment Studies 2 (CJ-DATS 2) was launched in 2008 with a focus on conducting implementation research in criminal justice settings. NIDA's ultimate goal for CJ-DATS 2 was to identify implementation strategies that maximize the likelihood of sustained delivery of evidence-based practices to improve offender drug abuse and HIV outcomes, and to decrease their risk of incarceration.

The Organizational Process Improvement Intervention (OPII) study (aka Assessment study) focused on implementing assessment and treatment planning processes. Screening and assessment were used to identify substance abuse-related problems and to develop programming to address the problems so identified.

The OPII study engaged corrections and treatment agencies to improve the quality of interagency communication through the effective use of assessment and case planning processes and treatment referrals. Both inter-agency and intra-agency change processes were targeted. A multi-phase implementation protocol was used, wherein agencies engaged in team development, needs assessment, planning, implementation, and sustainability in distinct steps. Early- and delayed-start sites allowed the research team to control for effects of environmental changes within states. The protocol targeted critical communications channels between otherwise often highly segregated correctional and treatment agencies.

Evaluation of the OPII used a multi-site cluster randomized design with multiple measures over the course of the intervention. Clusters consisted of a criminal justice agency and one or more community treatment providers that received referrals from that criminal justice agency. Each of the 9 centers had two clusters (one had three), and each cluster was randomized to an Early-Start or a Delayed-Start condition with multiple measures over the course of the intervention. After randomization, the Early-Start sites began the OPII, while the Delayed-Start sites conducted business as usual, without any additional intervention. After approximately 12 months, or when the Early-Start change team completed the Implementation phase, the Delayed-Start change team began to carry out the protocol.

Throughout the study period different subsets of individuals working at correctional facilities and treatment programs at the study sites were asked to complete surveys. During the Baseline period of the study survey data were collected from correctional staff, correctional directors, treatment staff, treatment directors, correctional executives and treatment executives. These data can be found in (DS1-DS12). The executive respondents provided information at the organizational level for the programs they oversaw (DS5, DS6). Next, Needs Assessments were completed by the change teams and their facilitators (DS13-DS14). The change teams and facilitators also responded to surveys on Process Improvement Planning (DS15-DS19). During the Implementation stage, surveys were administered to select substance abuse treatment programs, change team facilitators, change team members and the immediate supervisors of the change team members (DS20-DS27). Selected correctional and treatment staff members (in the Early-Start sites only) were asked to complete Follow-up surveys at the end of the OPII process (DS28-DS33). Staff members who completed surveys also provided demographic data (DS36-DS41). DS42 is a restricted use version of DS41. Change team members kept track of the time they spent on OPII activities (DS35). Change team success was evaluated by a subset of raters (DS34).

Surveys were administered at 21 study sites and there was a total of over 2,700 survey respondents.

The Epidemiologic Catchment Area (ECA) program of research was initiated in response to the 1977 report of the President's Commission on Mental Health. The purpose was to collect data on the prevalence and incidence of mental disorders and on the use of and need for services by the mentally ill. Independent research teams at five universities (Yale University, Johns Hopkins University, Washington University, Duke University, and University of California at Los Angeles), in collaboration with the National Institute for Mental Health, conducted the studies with a core of common questions and sample characteristics. The sites were areas that had previously been designated as Community Mental Health Center catchment areas: New Haven, Connecticut, Baltimore, Maryland, St. Louis, Missouri, Durham, North Carolina, and Los Angeles, California. Each site sampled over 3,000 community residents and 500 residents of institutions, yielding 20,861 respondents overall. The longitudinal ECA design incorporated two waves of personal interviews administered one year apart and a brief telephone interview in between (for the household sample). The diagnostic interview used in the ECA was the NIMH Diagnostic Interview Schedule (DIS), Version III (with the exception of the Yale Wave I survey, which used Version II). Diagnoses were categorized according to the DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, 3rd Edition (DSM-III). Diagnoses derived from the DIS include manic episode, dysthymia, bipolar disorder, single episode major depression, recurrent major depression, atypical bipolar disorder, alcohol abuse or dependence, drug abuse or dependence, schizophrenia, schizophreniform, obsessive compulsive disorder, phobia, somatization, panic, antisocial personality, and anorexia nervosa. The DIS uses the Mini-Mental State Examination (MMSE), which measures cognitive functioning, as an indirect measure of the DSM-III Organic Mental Disorders. In the ECA survey, this diagnosis is called cognitive impairment.

This collection features data from 17,327 participants across 2,005 variables. Data from the Los Angeles, California, Catchment (UCLA) are not included. Baseline data (Wave 1) and Wave 2 data were linked to the National Death Index through 2007, which includes primary and contributing causes of death, International Classification of Disease (ICD) codes, and nature of injury variables.

This study is part of the Seek, Test, Treat and Retain (STTR) Collaboration Project that involved over twenty studies in the fields of HIV and drug abuse. All studies were independently developed, but were chosen for the collaboration because they focused on one or more steps of the HIV treatment cascade: Seek, Test, Treat and Retain. As part of STTR Collaboration Project, the studies were grouped into Criminal Justice-related studies and Vulnerable Population-related studies. The data collected by these studies included twelve common domains (e.g., Demographic characteristics, Mental Health) in each of which a shared questionnaire or instrument was taken up by the studies and adapted to fit the study.

The specific aim for this study was to conduct a placebo-controlled, RCT of VIVITROL or (extended-release naltrexone) (XR-NTX 380mg) among HIV+ persons in jails and prisons meeting DSM-IV criteria for opioid dependence who are transitioning to the community. HIV treatment outcomes (HIV-1 RNA levels, CD4 count, HAART adherence, retention in care), substance abuse (time to relapse to opioid use, % opioid negative urines, opioid craving), adverse side effects and HIV risk behavior (sexual and drug-related risks) outcomes were compared in 150 recruited prisoners and jail detainees in CT and MA who were randomized 2:1 to either XR-NTX 380mg or XR-NTX-placebo. The primary outcome of interest was the proportion with a HIV-RNA less than 400 copies/mL at 6 months. Secondary outcomes included mean CD4 count, antiretroviral adherence, retention on HAART and in HIV care, HIV risk behaviors, time-to-relapse to opioid use, percent opioid negative urines, retention on XR-NTX 380mg and HIV quality of life. Primary and secondary outcomes were assessed for an additional 6 months after completion of the intervention.